pharmaceutical investing Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
pharmaceutical investing Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
pharmaceutical investing Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
pharmaceutical investing Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
pharmaceutical investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
pharmaceutical investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
pharmaceutical investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
pharmaceutical investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Oreterra Receives Conditional Approval to Sell Option to Buy Down Newmont Lake Royalty to Enduro Metals
Harvest Gold Announces Non-Brokered Private Placement To Fund 2026 Drill Program On Its Flagship Mosseau Property
